Avalglucosidase Alfa
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II Pompe Disease
Conditions
Glycogen Storage Disease Type II Pompe Disease
Trial Timeline
Feb 27, 2014 → Dec 12, 2022
NCT ID
NCT02032524About Avalglucosidase Alfa
Avalglucosidase Alfa is a phase 2 stage product being developed by Sanofi for Glycogen Storage Disease Type II Pompe Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02032524. Target conditions include Glycogen Storage Disease Type II Pompe Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06666413 | Approved | Recruiting |
| NCT04910776 | Phase 3 | Active |
| NCT02032524 | Phase 2 | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II Pompe Disease